Understand the significant growth trajectory of the Minoxidil 5% segment, which is expected to reach US$1.6 Billion by 2030 ...

Over the past six decades, hundreds of millions of people have taken Xanax or one of its relatives in the benzodiazepine family for a range of ...

The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Shares of Pfizer Inc. PFE slid 2.44% to $25.99 Tuesday, on what proved to be an all-around poor trading session for the stock ...

A Brooklyn brownstone with a long history starting with the Pfizer family has hit the market for $10.35 million—after setting ...

Freshfields represented Moderna, while Taylor Wessing advised BioNTech and Munich IP-firm df-mp was counsel to Pfizer.

Researchers racing to develop bird flu vaccines for humans have turned to a cutting-edge technology that enabled the rapid development of lifesaving covid shots.

Freshfields has won a Düsseldorf regional court patent dispute on behalf of client Moderna against German COVID-19 vaccine ...